Key statistics
As of last trade Elanco Animal Health Inc (ELAN:NYQ) traded at 25.05, -9.63% below its 52-week high of 27.72, set on Feb 25, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 25.46 |
|---|---|
| High | 25.48 |
| Low | 24.52 |
| Bid | 25.04 |
| Offer | 25.06 |
| Previous close | 26.09 |
| Average volume | 5.21m |
|---|---|
| Shares outstanding | 497.17m |
| Free float | 490.97m |
| P/E (TTM) | -- |
| Market cap | 12.97bn USD |
| EPS (TTM) | -0.4848 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 20:07 GMT.
More ▼
- Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results
- Elanco to Participate in Upcoming Investor Conferences
- Elanco Announces Updates to Board of Directors
- Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement
- Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference
- Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis
- Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs
- Elanco Investor Day Defines New Era as Sustainable Growth Company
More ▼
